GENinCode PLC (LSX:A3C31Y) Financings

GENinCode PLC

Financings

RaiseDateIn US dollars
Private placement of new Ordinary Shares (Additional Subscription Shares)
Announced: £580,000 · GBX 1 a share
Use of proceeds: Additional funding and a longer cash runway while providing the FDA with updates for the De Novo application for its CARDIO inCode-Score test
Feb 6, 2026US$789,256
New Ordinary Shares (WRAP Retail Offer)
Closed: £200,000 raised · GBX 1 a share · Winterflood Securities Limited
Dealers: Winterflood Securities Limited
Jan 26, 2026US$273,712
Private placement of new ordinary shares (Placing Shares)
Announced: £2.6M · GBX 1 a share · Cavendish Capital Markets Limited +2
Dealers: Cavendish Capital Markets Limited (co-lead), Oberon Capital (co-lead), Turner Pope Investments (TPI) Ltd (co-lead)
Use of proceeds: US commercialisation and scale-up, EU and UK expansion, fundraising costs and general working capital
Jan 21, 2026US$3.49M
Private placement of new ordinary shares (Subscription Shares)
Announced: £900,000 · GBX 1 a share
Buyers: Nestor Oller (entities associated with existing shareholder Nestor Oller, with certain Directors, to subscribe for 87,300,000 Subscription Shares raising £0.9 million in aggregate)
Insiders: Certain Directors intend to subscribe alongside entities associated with Nestor Oller
Jan 21, 2026US$1.21M
Private placement of new ordinary shares
Update: Cavendish Capital Markets Limited +1
Dealers: Cavendish Capital Markets Limited (co-lead), Oberon Capital (co-lead)
Buyers: Santi-1990 SL (Nestor Oller) (9,459,460 shares)
Mar 3, 2025

Read by 6ix AI from the company's releases